NO744074L - - Google Patents

Info

Publication number: NO744074L
Authority: NO; Norway
Prior art keywords: thromboplastin; tissue; agent according; blood; minutes
Prior art date: 1973-11-13

Application number

NO744074A

Other languages

English (en)

Norwegian (no)

Inventor

H Trobisch

H Schwinn

Original Assignee

Behringwerke Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1973-11-13

Filing date

1974-11-12

Publication date

1975-06-09

1973-11-13 Priority claimed from DE19732356493 external-priority patent/DE2356493C3/de

1974-11-12 Application filed by Behringwerke Ag filed Critical Behringwerke Ag

1975-06-09 Publication of NO744074L publication Critical patent/NO744074L/no

Links

PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 claims description 34
108010000499 Thromboplastin Proteins 0.000 claims description 33
102000002262 Thromboplastin Human genes 0.000 claims description 33
230000015271 coagulation Effects 0.000 claims description 26
238000005345 coagulation Methods 0.000 claims description 26
238000000605 extraction Methods 0.000 claims description 14
239000003795 chemical substances by application Substances 0.000 claims description 12
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 claims description 9
PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 9
229910001424 calcium ion Inorganic materials 0.000 claims description 9
229910052748 manganese Inorganic materials 0.000 claims description 9
239000011572 manganese Substances 0.000 claims description 9
238000000034 method Methods 0.000 claims description 9
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 8
229940039227 diagnostic agent Drugs 0.000 claims description 8
239000000032 diagnostic agent Substances 0.000 claims description 8
239000000243 solution Substances 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 7
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 claims description 7
229960003964 deoxycholic acid Drugs 0.000 claims description 7
230000002885 thrombogenetic effect Effects 0.000 claims description 7
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 6
108010014173 Factor X Proteins 0.000 claims description 6
229930195725 Mannitol Natural products 0.000 claims description 6
239000008280 blood Substances 0.000 claims description 6
210000004369 blood Anatomy 0.000 claims description 6
229940012426 factor x Drugs 0.000 claims description 6
239000000594 mannitol Substances 0.000 claims description 6
235000010355 mannitol Nutrition 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 5
239000003381 stabilizer Substances 0.000 claims description 5
239000007900 aqueous suspension Substances 0.000 claims description 4
229910001385 heavy metal Inorganic materials 0.000 claims description 4
210000005059 placental tissue Anatomy 0.000 claims description 4
239000000654 additive Substances 0.000 claims description 3
230000000996 additive effect Effects 0.000 claims description 3
230000023555 blood coagulation Effects 0.000 claims description 3
RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 claims description 3
239000000284 extract Substances 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
238000000926 separation method Methods 0.000 claims description 3
241001465754 Metazoa Species 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims description 2
210000005013 brain tissue Anatomy 0.000 claims description 2
150000005846 sugar alcohols Chemical class 0.000 claims description 2
239000002253 acid Substances 0.000 claims 2
239000012670 alkaline solution Substances 0.000 claims 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims 1
229960001231 choline Drugs 0.000 claims 1
150000002016 disaccharides Chemical class 0.000 claims 1
150000002772 monosaccharides Chemical class 0.000 claims 1
230000006641 stabilisation Effects 0.000 claims 1
238000011105 stabilization Methods 0.000 claims 1
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
210000002826 placenta Anatomy 0.000 description 7
210000004556 brain Anatomy 0.000 description 6
241000283973 Oryctolagus cuniculus Species 0.000 description 5
108010094028 Prothrombin Proteins 0.000 description 5
239000000203 mixture Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
102100023804 Coagulation factor VII Human genes 0.000 description 4
108010023321 Factor VII Proteins 0.000 description 4
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
102100027378 Prothrombin Human genes 0.000 description 4
108090000190 Thrombin Proteins 0.000 description 4
239000001110 calcium chloride Substances 0.000 description 4
229910001628 calcium chloride Inorganic materials 0.000 description 4
230000000694 effects Effects 0.000 description 4
229940039716 prothrombin Drugs 0.000 description 4
235000011121 sodium hydroxide Nutrition 0.000 description 4
229960004072 thrombin Drugs 0.000 description 4
238000005406 washing Methods 0.000 description 4
102000015081 Blood Coagulation Factors Human genes 0.000 description 3
108010039209 Blood Coagulation Factors Proteins 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
239000003114 blood coagulation factor Substances 0.000 description 3
239000011575 calcium Substances 0.000 description 3
238000010908 decantation Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
230000001575 pathological effect Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
229940012413 factor vii Drugs 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000000463 material Substances 0.000 description 2
230000003169 placental effect Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
-1 UC>2 - Chemical class 0.000 description 1
239000003146 anticoagulant agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
208000015294 blood coagulation disease Diseases 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
230000009852 coagulant defect Effects 0.000 description 1
229940105772 coagulation factor vii Drugs 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
201000007386 factor VII deficiency Diseases 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
235000013372 meat Nutrition 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
ZUUZGQPEQORUEV-UHFFFAOYSA-N tetrahydrate;hydrochloride Chemical compound O.O.O.O.Cl ZUUZGQPEQORUEV-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000732 tissue residue Toxicity 0.000 description 1
239000011701 zinc Substances 0.000 description 1
NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
229960001763 zinc sulfate Drugs 0.000 description 1
229910000368 zinc sulfate Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/56—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving blood clotting factors, e.g. involving thrombin, thromboplastin, fibrinogen
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/745—Assays involving non-enzymic blood coagulation factors
- G01N2333/7452—Thrombomodulin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Engineering & Computer Science (AREA)
Microbiology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Peptides Or Proteins (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO744074A 1973-11-13 1974-11-12 NO744074L (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19732356493 DE2356493C3 (de)		1973-11-13	Verfahren zur Herstellung eines Thromboplastins und diagnostisches Mittel zur Kontrolle der Gerinnungsfähigkeit des Blutes

Publications (1)

Publication Number	Publication Date
NO744074L true NO744074L (de)	1975-06-09

Family

ID=5897898

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO744074A NO744074L (de)	1973-11-13	1974-11-12

Country Status (20)

Country	Link
US (1)	US3983004A (de)
JP (1)	JPS5843080B2 (de)
AT (1)	AT338981B (de)
AU (1)	AU497109B2 (de)
BE (1)	BE822134A (de)
BR (1)	BR7409498A (de)
CA (1)	CA1043702A (de)
CH (1)	CH611426A5 (de)
DK (1)	DK138256C (de)
ES (1)	ES431736A1 (de)
FI (1)	FI327274A (de)
FR (1)	FR2251002B1 (de)
GB (1)	GB1490209A (de)
IE (1)	IE40114B1 (de)
IT (1)	IT1025596B (de)
LU (1)	LU71264A1 (de)
NL (1)	NL7414604A (de)
NO (1)	NO744074L (de)
SE (1)	SE7414232L (de)
ZA (1)	ZA747287B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2525804B2 (de) *	1975-06-10	1980-04-03	Behringwerke Ag, 3550 Marburg	Stabiler Clumping-Faktor, Verwendung desselben zum Nachweis von Fibrinogen- und Fibrinspaltprodukten und Herstellung desselben
US4116635A (en) *	1977-03-14	1978-09-26	Jaeger Mark A	General purpose in vitro anticoagulant
DE2757992A1 (de) *	1977-12-24	1979-06-28	Boehringer Mannheim Gmbh	Verfahren zur prothrombin-bestimmung
DE2836362A1 (de) *	1978-08-19	1980-03-06	Behringwerke Ag	Diagnostisches mittel
US4276383A (en) *	1979-08-02	1981-06-30	The United States Of America As Represented By The Department Of Health, Education & Welfare	Clot lysing timer
DE3150596A1 (de) *	1981-12-21	1983-06-30	Boehringer Mannheim Gmbh, 6800 Mannheim	Verfahren zur herstellung von gewebsthromboplastin
DE3413311A1 (de) *	1984-04-09	1985-10-17	Behringwerke Ag, 3550 Marburg	Reagenz zur bestimmung der thromboplastinzeit
NO852655L (no) *	1985-06-05	1986-12-08	Bio Data Corp	Fremgangsmaate ved fremstilling av koaguleringsreagens for blodplasma i mikrokonsentrert tablettform.
US4755461A (en) *	1986-04-17	1988-07-05	Bio/Data Corporation	Tableted blood plasma microconcentrated thromboplastin coagulation reagent
US5270451A (en) *	1988-11-23	1993-12-14	Baxter Diagnostics Inc.	Extraction method for preparing thromboplastin reagents
US5281528A (en) *	1989-12-18	1994-01-25	Warner-Lambert Company	Process for purified thromboplastin for ultra-pure thrombin preparation
US6261792B1 (en)	1990-12-07	2001-07-17	The Liposome Company, Inc.	Lipid-dependent diagnostic assays
JP3180824B2 (ja) *	1991-08-30	2001-06-25	シスメックス株式会社	血液凝固試薬
US5780255A (en) *	1995-06-09	1998-07-14	Instrumentation Laboratory, S.P.A.	Protein C pathway screening test
AU1311800A (en)	1998-10-07	2000-04-26	Sigma-Aldrich Co.	Thromboplastin reagents and methods for preparing and using such reagents
US7148067B2 (en) *	2004-08-31	2006-12-12	The Board Of Trustees Of The University Of Illinois	Thromboplastin reagents
WO2006088741A2 (en) *	2005-02-16	2006-08-24	The Board Of Trustees Of The University Of Illinois	Procoagulants based on metal-chelating lipids
EP1869082B1 (de) *	2005-03-04	2011-04-13	The Board Of Trustees Of The University Of Illinois	Modulator von coagulationskaskaden und fibrinolytischen kaskaden
WO2009046194A2 (en) *	2007-10-05	2009-04-09	The Board Of Trustees Of The University Of Illinois	Fibrin sealant
WO2009061697A1 (en)	2007-11-09	2009-05-14	The Board Of Trustees Of The University Of Illinois	Anticoagulant antagonist and hemophilia procoagulant
CN112740034A (zh) *	2018-09-25	2021-04-30	积水医疗株式会社	测定凝血时间的方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2687980A (en) *	1948-09-15	1954-08-31	Ernest W Blanchard	Thromboplastin product and method for preparing same
US2847347A (en) *	1954-05-27	1958-08-12	Ortho Pharmacentical Corp	Preparation of improved thromboplastin
US3522148A (en) *	1965-08-13	1970-07-28	Dade Reagents Inc	Stabilized thromboplastin preparation
BE787961A (fr) *	1971-08-24	1973-02-26	Behringwerke Ag	Procede d'isolement d'une matiere thromboplastique et medicament contenant ladite matiere

1974
- 1974-11-07 ES ES431736A patent/ES431736A1/es not_active Expired
- 1974-11-08 NL NL7414604A patent/NL7414604A/xx not_active Application Discontinuation
- 1974-11-08 CH CH1492374A patent/CH611426A5/xx not_active IP Right Cessation
- 1974-11-11 IT IT29305/74A patent/IT1025596B/it active
- 1974-11-11 LU LU71264A patent/LU71264A1/xx unknown
- 1974-11-11 AU AU75228/74A patent/AU497109B2/en not_active Expired
- 1974-11-11 US US05/522,759 patent/US3983004A/en not_active Expired - Lifetime
- 1974-11-11 FI FI3272/74A patent/FI327274A/fi unknown
- 1974-11-12 AT AT903974A patent/AT338981B/de not_active IP Right Cessation
- 1974-11-12 GB GB48934/74A patent/GB1490209A/en not_active Expired
- 1974-11-12 NO NO744074A patent/NO744074L/no unknown
- 1974-11-12 DK DK588174A patent/DK138256C/da active
- 1974-11-12 CA CA213,489A patent/CA1043702A/en not_active Expired
- 1974-11-12 BR BR9498/74A patent/BR7409498A/pt unknown
- 1974-11-12 IE IE2323/74A patent/IE40114B1/xx unknown
- 1974-11-13 SE SE7414232A patent/SE7414232L/xx unknown
- 1974-11-13 FR FR7437376A patent/FR2251002B1/fr not_active Expired
- 1974-11-13 ZA ZA00747287A patent/ZA747287B/xx unknown
- 1974-11-13 JP JP49130095A patent/JPS5843080B2/ja not_active Expired
- 1974-11-13 BE BE150453A patent/BE822134A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
ZA747287B (en)	1975-11-26
BE822134A (fr)	1975-05-13
DK588174A (de)	1975-07-14
ATA903974A (de)	1977-01-15
AT338981B (de)	1977-09-26
US3983004A (en)	1976-09-28
JPS5085393A (de)	1975-07-09
BR7409498A (pt)	1976-05-25
LU71264A1 (de)	1976-09-06
FR2251002B1 (de)	1978-06-16
FR2251002A1 (de)	1975-06-06
IE40114B1 (en)	1979-03-14
SE7414232L (de)	1975-05-14
DE2356493B2 (de)	1976-09-16
AU7522874A (en)	1976-05-13
CH611426A5 (de)	1979-05-31
AU497109B2 (en)	1978-11-30
JPS5843080B2 (ja)	1983-09-24
FI327274A (de)	1975-05-14
DK138256C (da)	1979-01-22
DK138256B (da)	1978-08-07
GB1490209A (en)	1977-10-26
DE2356493A1 (de)	1975-05-15
IT1025596B (it)	1978-08-30
CA1043702A (en)	1978-12-05
NL7414604A (nl)	1975-05-15
ES431736A1 (es)	1977-05-16
IE40114L (en)	1975-05-13

Publication	Publication Date	Title
NO744074L (de)	1975-06-09
US5254350A (en)	1993-10-19	Method of preparing a thromboplastin extract
JPH0339267B2 (de)	1991-06-13
Finn	1932	Denaturation of proteins in muscle juice by freezing
US4399003A (en)	1983-08-16	Method and kit for diagnosing a patient's proneness to develop calcium oxalate kidney stones
Gatzy et al.	1968	Isolated epithelial cells of the toad bladder: Their preparation, oxygen consumption, and electrolyte content
Wolfrom et al.	1945	The relation between the structure of heparin and its anticoagulant activity
US4458015A (en)	1984-07-03	Reagent for the optical determination of the blood coagulation
NO150297B (no)	1984-06-12	Lyofilisert kollagenpreparat og fremgangsmaate for dets fremstilling
Wu et al.	1927	Colorimetric determination of proteins in plasma, cerebrospinal fluid and urine
JP3180824B2 (ja)	2001-06-25	血液凝固試薬
JPS6327660B2 (de)	1988-06-03
Erwin et al.	1994	Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton
Abdon et al.	1944	Is any Free Acetylcholine Preformed in Resting Muscles or in the Hertrt? 1
Bigland et al.	1961	Chicken prothrombin, thrombin, and fibrinogen
US3813465A (en)	1974-05-28	Cytological preservative and mucolytic composition
DE2356493C3 (de)	1977-05-05	Verfahren zur Herstellung eines Thromboplastins und diagnostisches Mittel zur Kontrolle der Gerinnungsfähigkeit des Blutes
Edelfors	1977	The influence of lithium on water binding ability, consistency and macromolecules in the rat brain
DE1943881C3 (de)	1979-03-22	Verfahren zur quantitativen Bestimmung der Thrombinaktivität in Blutplasma und dessen Fraktionen
JPH0560764A (ja)	1993-03-12	血液凝固測定方法
Loeliger et al.	1974	Reliability of laboratory tests for the control of oral anticoagulation
JOB et al.	0	different regions and layers of intestinal muscle
Glendening et al.	1955	Rapid determination of plasma fibrinogen
Futterman	1974	[29] Rhodopsin from bovine retinas
Telfer	1949	The concentration of biliary constituents in the human gall-bladder